Difference between revisions of "Breast cancer, BRCA-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 62: Line 62:
 
|}
 
|}
 
''Patients in OlympiAD had confirmed deleterious or suspected deleterious germline BRCA mutation.''
 
''Patients in OlympiAD had confirmed deleterious or suspected deleterious germline BRCA mutation.''
−
====Chemotherapy====
+
====Targeted therapy====
 
*[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8
 
*[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8
  
Line 85: Line 85:
 
|-
 
|-
 
|}
 
|}
−
====Chemotherapy====
+
====Targeted therapy====
 
*[[Olaparib (Lynparza)]] 100 mg PO twice per day
 
*[[Olaparib (Lynparza)]] 100 mg PO twice per day
  
Line 106: Line 106:
 
|}
 
|}
 
''Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.''
 
''Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.''
−
====Chemotherapy====
+
====Targeted therapy====
 
*[[Olaparib (Lynparza)]] 300 mg PO twice per day
 
*[[Olaparib (Lynparza)]] 300 mg PO twice per day
  
Line 124: Line 124:
 
|}
 
|}
 
''Patients in Study 42 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.''
 
''Patients in Study 42 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.''
−
====Chemotherapy====
+
====Targeted therapy====
 
*[[Olaparib (Lynparza)]] 400 mg PO twice per day
 
*[[Olaparib (Lynparza)]] 400 mg PO twice per day
  
Line 160: Line 160:
 
|-
 
|-
 
|}
 
|}
−
====Chemotherapy====
+
====Targeted therapy====
 
*[[Talazoparib (Talzenna)]] 1 mg PO once per day
 
*[[Talazoparib (Talzenna)]] 1 mg PO once per day
  

Revision as of 15:03, 24 August 2020

Section editor transclusions

10 regimens on this page
13 variants on this page

Note: this page has regimens which are specific to breast cancer that is BRCA-mutated. Please see the main breast cancer page for other chemotherapy regimens.


Guidelines

ESMO

Advanced or metastatic disease, all lines of therapy

Capecitabine monotherapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Robson et al. 2017 (OlympiAD) 2014-2015 Phase III (C) Olaparib Inferior PFS

Patients in OlympiAD had confirmed deleterious or suspected deleterious germline BRCA mutation.

Chemotherapy

21-day cycles

References

  1. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
    1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed

Eribulin monotherapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Robson et al. 2017 (OlympiAD) 2014-2015 Phase III (C) Olaparib Inferior PFS

Patients in OlympiAD had confirmed deleterious or suspected deleterious germline BRCA mutation.

Targeted therapy

21-day cycles

References

  1. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
    1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed

Olaparib monotherapy

back to top

Regimen variant #1, 100 mg twice per day

Study Evidence
Tutt et al. 2010 Phase II

Targeted therapy

Continued indefinitely

Regimen variant #2, 300 mg twice per day

Study Years of enrollment Evidence Comparator Comparative Efficacy
Robson et al. 2017 (OlympiAD) 2014-2015 Phase III (E-RT-switch-ooc) 1. Capecitabine
2. Eribulin
3. Vinorelbine 		Superior PFS

Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.

Targeted therapy

Continued indefinitely

Regimen variant #3, 400 mg twice per day

Study Evidence
Tutt et al. 2010 Phase II
Kaufman et al. 2014 (Study 42) Phase II

Patients in Study 42 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.

Targeted therapy

Continued indefinitely

References

  1. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. link to original article PubMed
  2. Study 42: Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed
  3. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
    1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed

Talazoparib monotherapy

back to top

Regimen

FDA-recommended dose
Study Years of enrollment Evidence Comparator Comparative Efficacy
Litton et al. 2018 (EMBRACA) 2013-2017 Phase III (E-RT-switch-ooc) Physician's choice of:
1. Capecitabine
2. Eribulin
3. Gemcitabine
4. Vinorelbine 		Superior PFS

Targeted therapy

Continued indefinitely

References

  1. EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains protocol PubMed

Vinorelbine monotherapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Robson et al. 2017 (OlympiAD) 2014-2015 Phase III (C) Olaparib Inferior PFS

Patients had confirmed deleterious or suspected deleterious germline BRCA mutation.

Chemotherapy

21-day cycles

References

  1. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
    1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed

Additional resources

back to top
Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer,_BRCA-mutated&oldid=45316"